Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

IKT US Equity

Inhibikase Therapeutics, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1750149 · FY ends Dec 31
$2.45
+0.05 (+2.08%)
USD · as of 2026-08-19 · marketstack
4 8-K filings · 0 13D · 6 13G
DateEventWhat happened / filerSource
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by PERCEPTIVE ADVISORS LLCsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Nantahala Capital Management, LLCsec.gov ↗
2026-08-1313G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Sands Capital Life Sciences Pulse Fund II, L.P.sec.gov ↗
2026-08-118-K 2.02Results of operations and financial condition (earnings)earnings history (EARN) →sec.gov ↗
2026-07-3113G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by RA CAPITAL MANAGEMENT, L.P.sec.gov ↗
2026-07-298-K 3.02Unregistered sales of equity securitiessec.gov ↗
2026-07-2813GSchedule 13G filed — ≥5% beneficial owner (passive) · by BlackRock, Inc.sec.gov ↗
2026-07-238-K 7.01Regulation FD disclosuresec.gov ↗
2026-07-1713GSchedule 13G filed — ≥5% beneficial owner (passive) · by RA CAPITAL MANAGEMENT, L.P.sec.gov ↗
2026-07-148-K 8.01Other eventssec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-07-14

Every row is a filed document, checked against its EDGAR index.